Literature DB >> 25717200

Inpatient and outpatient pharmacy monitoring of oral antineoplastic medications.

Ross Jason Bindler1.   

Abstract

Entities:  

Year:  2015        PMID： 25717200      PMCID： PMC4336007          DOI： 10.1310/hpj5002-91

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


× No keyword cloud information.
  11 in total

1.  Impact of clinical oral chemotherapy program on wastage and hospitalizations.

Authors:  Nikhil Khandelwal; Ian Duncan; Tamim Ahmed; Elan Rubinstein; Cheryl Pegus
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

2.  Medication safety of five oral chemotherapies: a proactive risk assessment.

Authors:  Saul N Weingart; Justin Spencer; Stephanie Buia; Deborah Duncombe; Prabhjyot Singh; Mrinalini Gadkari; Maureen Connor
Journal:  J Oncol Pract       Date:  2010-12-08       Impact factor: 3.840

Review 3.  Does applying technology throughout the medication use process improve patient safety with antineoplastics?

Authors:  Joseph Bubalo; Bruce A Warden; Joshua J Wiegel; Tess Nishida; Evelyn Handel; Leanne M Svoboda; Lam Nguyen; P Neil Edillo
Journal:  J Oncol Pharm Pract       Date:  2013-12-19       Impact factor: 1.809

4.  Early discontinuation of tamoxifen: a lesson for oncologists.

Authors:  Thomas I Barron; Róisín Connolly; Kathleen Bennett; John Feely; M John Kennedy
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

5.  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.

Authors:  Dawn L Hershman; Lawrence H Kushi; Theresa Shao; Donna Buono; Aaron Kershenbaum; Wei-Yann Tsai; Louis Fehrenbacher; Scarlett Lin Gomez; Sunita Miles; Alfred I Neugut
Journal:  J Clin Oncol       Date:  2010-06-28       Impact factor: 44.544

Review 6.  Patient adherence and persistence with oral anticancer treatment.

Authors:  Kathryn Ruddy; Erica Mayer; Ann Partridge
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

7.  Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.

Authors:  Cynthia Owusu; Diana S M Buist; Terry S Field; Timothy L Lash; Soe Soe Thwin; Ann M Geiger; Virginia P Quinn; Floyd Frost; Marianne Prout; Marianne Ulcickas Yood; Feifei Wei; Rebecca A Silliman
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544

Review 8.  Overview of the changing paradigm in cancer treatment: oral chemotherapy.

Authors:  Joseph Aisner
Journal:  Am J Health Syst Pharm       Date:  2007-05-01       Impact factor: 2.637

9.  The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you?

Authors:  Phyllis M Lau; Kay Stewart; Michael Dooley
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

10.  Partial fill strategies for oral oncolytics to reduce waste and drive persistency.

Authors:  Atheer A Kaddis
Journal:  Am J Manag Care       Date:  2013 Jan-Feb       Impact factor: 2.229
View more
  2 in total

1.  Medication Therapy Management for Patients Receiving Oral Chemotherapy Agents at a Community Oncology Center: A Pilot Study.

Authors:  Nathan S Bertsch; Ross J Bindler; Poppy L Wilson; Anne P Kim; Beverly Ward
Journal:  Hosp Pharm       Date:  2016-10

Review 2.  Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account.

Authors:  Roberto Collado-Borrell; Vicente Escudero-Vilaplana; Rosa Romero-Jiménez; Irene Iglesias-Peinado; Ana Herranz-Alonso; María Sanjurjo-Sáez
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-17       Impact factor: 4.553
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.